Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
Aimo, Alberto (Fondazione Toscana Gabriele Monasterio)
Spitaleri, Giosafat (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Nieri, Dario (Pisa University Hospital)
Tavanti, Laura Maria (Pisa University Hospital)
Meschi, Claudia (University of Pisa)
Panichella, Giorgia (Scuola Superiore Sant'Anna)
Lupón, Josep (Instituto de Salud Carlos III)
Pistelli, Francesco (Pisa University Hospital)
Carrozzi, Laura (University of Pisa)
Bayés-Genís, Antoni (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Emdin, Michele (Fondazione Toscana Gabriele Monasterio)
Universitat Autònoma de Barcelona

Date:	2022
Abstract:	Pirfenidone (PFD) slows the progression of idiopathic pulmonary fibrosis (IPF) by inhibiting the exaggerated fibrotic response and possibly through additional mechanisms, such as anti-inflammatory effects. PFD has also been evaluated in other fibrosing lung diseases. Myocardial fibrosis is a common feature of several heart diseases and the progressive deposition of extracellular matrix due to a persistent injury to cardiomyocytes may trigger a vicious cycle that leads to persistent structural and functional alterations of the myocardium. No primarily antifibrotic medications are used to treat patients with heart failure. There is some evidence that PFD has antifibrotic actions in various animal models of cardiac disease and a phase II trial on patients with heart failure and preserved ejection fraction has yielded positive results. This review summarises the evidence about the possible mechanisms of IPF and modulation by PFD, the main results about IPF or non-IPF interstitial pneumonias and also data about PFD as a potential protective cardiac drug.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Animal models ; Clinical trials ; Heart ; Idiopathic pulmonary fibrosis ; Lung ; Pirfenidone
Published in:	Cardiac Failure Review, Vol. 8 (april 2022) , ISSN 2057-7559

DOI: 10.15420/cfr.2021.30
PMID: 35516794

8 p, 275.5 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles